Clinical Trial Update: Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of a recombinant chimeric anti-CD20 monoclonal antibody in patients with B-cell non-Hodg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Recombinant chimeric anti-CD20 monoclonal antibody

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: B-cell Non Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED